Keywords
Last Name
Institution

Randall Holcombe

TitlePROFESSOR
InstitutionMount Sinai
DepartmentHematology and Medical Oncology
Address1470 Madison Avenue
3rd floor
New York NY 10029
Phone212-241-6756

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013 Dec; 23(6):498-501.
      View in: PubMed
    2. Martinez M, Ono N, Planutiene M, Planutis K, Nelson EL, Holcombe RF. Correction: Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy. Cancer Cell Int. 2013; 13(1):80.
      View in: PubMed
    3. Planutis K, Planutiene M, Nguyen AV, Moyer MP, Holcombe RF. Invasive colon cancer, but not non-invasive adenomas induce a gradient effect of Wnt pathway receptor frizzled 1 (Fz1) expression in the tumor microenvironment. J Transl Med. 2013; 11:50.
      View in: PubMed
    4. Alistar A, Sung M, Kim M, Holcombe RF. Clinical pathways for pancreatic neuroendocrine tumors. J Gastrointest Cancer. 2012 Dec; 43(4):532-40.
      View in: PubMed
    5. Dellinger TH, Planutis K, Jandial DD, Eskander RN, Martinez ME, Zi X, Monk BJ, Holcombe RF. Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer. Gynecol Oncol. 2012 Aug; 126(2):259-67.
      View in: PubMed
    6. Martinez M, Ono N, Planutiene M, Planutis K, Nelson EL, Holcombe RF. Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy. Cancer Cell Int. 2012; 12(1):2.
      View in: PubMed
    7. Dellinger TH, Planutis K, Tewari KS, Holcombe RF. Role of canonical Wnt signaling in endometrial carcinogenesis. Expert Rev Anticancer Ther. 2012 Jan; 12(1):51-62.
      View in: PubMed
    8. Planutiene M, Planutis K, Holcombe RF. Lymphoid enhancer-binding factor 1, a representative of vertebrate-specific Lef1/Tcf1 sub-family, is a Wnt-beta-catenin pathway target gene in human endothelial cells which regulates matrix metalloproteinase-2 expression and promotes endothelial cell invasion. Vasc Cell. 2011; 3:28.
      View in: PubMed
    9. Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, Gutheil JC, Tsao CJ. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011 Aug; 68(2):539-45.
      View in: PubMed
    10. Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1595-602.
      View in: PubMed
    11. Najdi R, Holcombe RF, Waterman ML. Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog. 2011; 10:5.
      View in: PubMed
    12. Nguyen AV, Albers CG, Holcombe RF. Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. Int J Mol Med. 2010 Jul; 26(1):121-5.
      View in: PubMed
    13. Holcombe RF, Hollinger KJ. Mission-focused, productivity-based model for sustainable support of academic hematology/oncology faculty and divisions. J Oncol Pract. 2010 Mar; 6(2):74-9.
      View in: PubMed
    14. Najdi R, Syed A, Arce L, Theisen H, Ting JH, Atcha F, Nguyen AV, Martinez M, Holcombe RF, Edwards RA, Marsh JL, Waterman ML. A Wnt kinase network alters nuclear localization of TCF-1 in colon cancer. Oncogene. 2009 Nov 26; 28(47):4133-46.
      View in: PubMed
    15. Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Planutis K, Hope C, Holcombe RF. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res. 2009; 1:25-37.
      View in: PubMed
    16. Tang Y, Simoneau AR, Liao WX, Yi G, Hope C, Liu F, Li S, Xie J, Holcombe RF, Jurnak FA, Mercola D, Hoang BH, Zi X. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther. 2009 Feb; 8(2):458-68.
      View in: PubMed
    17. Ehsanipoor RM, Rajan P, Holcombe RF, Wing DA. Limitations of ADAMTS-13 activity level in diagnosing thrombotic thrombocytopenic purpura in pregnancy. Clin Appl Thromb Hemost. 2009 Oct; 15(5):585-7.
      View in: PubMed
    18. Hope C, Planutis K, Planutiene M, Moyer MP, Johal KS, Woo J, Santoso C, Hanson JA, Holcombe RF. Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention. Mol Nutr Food Res. 2008 Jun; 52 Suppl 1:S52-61.
      View in: PubMed
    19. Chang KJ, Lee JG, Holcombe RF, Kuo J, Muthusamy R, Wu ML. Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol. 2008 Feb; 5(2):107-11.
      View in: PubMed
    20. Planutis K, Planutiene M, Holcombe RF. In situ hybridization to evaluate the expression of Wnt and frizzled genes in mammalian tissues. Methods Mol Biol. 2008; 468:231-41.
      View in: PubMed
    21. Planutis K, Planutiene M, Holcombe RF. Coculture methodologies for the study of Wnt signals. Methods Mol Biol. 2008; 468:255-61.
      View in: PubMed
    22. Gatcliffe TA, Monk BJ, Planutis K, Holcombe RF. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer. 2008 Sep-Oct; 18(5):954-62.
      View in: PubMed
    23. You J, Nguyen AV, Albers CG, Lin F, Holcombe RF. Wnt pathway-related gene expression in inflammatory bowel disease. Dig Dis Sci. 2008 Apr; 53(4):1013-9.
      View in: PubMed
    24. You XJ, Bryant PJ, Jurnak F, Holcombe RF. Expression of Wnt pathway components frizzled and disheveled in colon cancer arising in patients with inflammatory bowel disease. Oncol Rep. 2007 Sep; 18(3):691-4.
      View in: PubMed
    25. Guo Y, Zi X, Koontz Z, Kim A, Xie J, Gorlick R, Holcombe RF, Hoang BH. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res. 2007 Jul; 25(7):964-71.
      View in: PubMed
    26. Planutis K, Planutiene M, Moyer MP, Nguyen AV, PĂ©rez CA, Holcombe RF. Regulation of norrin receptor frizzled-4 by Wnt2 in colon-derived cells. BMC Cell Biol. 2007; 8:12.
      View in: PubMed
    27. Ou SH, Holcombe RF. Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe. Drugs. 2007; 67(4):611-2.
      View in: PubMed
    28. Zell JA, McEligot AJ, Ziogas A, Holcombe RF, Anton-Culver H. Differential effects of wine consumption on colorectal cancer outcomes based on family history of the disease. Nutr Cancer. 2007; 59(1):36-45.
      View in: PubMed
    29. Holcombe RF. Reengineering the clinical research enterprise: will the new vision for translational and clinical science be successful without more support for mentors? J Investig Med. 2006 Jul; 54(5):231-4.
      View in: PubMed
    30. Holcombe RF, McLaren CE, Milovanovic T. Immunomodulation with low dose levamisole in patients with colonic polyps. Cancer Detect Prev. 2006; 30(1):94-8.
      View in: PubMed
    31. Choi J, Kong K, Mozaffar T, Holcombe RF. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs. 2006 Jan; 17(1):103-5.
      View in: PubMed
    32. Zi X, Guo Y, Simoneau AR, Hope C, Xie J, Holcombe RF, Hoang BH. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res. 2005 Nov 1; 65(21):9762-70.
      View in: PubMed
    33. Nguyen A, Rosner A, Milovanovic T, Hope C, Planutis K, Saha B, Chaiwun B, Lin F, Imam SA, Marsh JL, Holcombe RF. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression. Int J Oncol. 2005 Oct; 27(4):949-56.
      View in: PubMed
    34. Holcombe RF. Viewpoint: who's watching out for the clinical academician? Acad Med. 2005 Oct; 80(10):905-7.
      View in: PubMed
    35. Byun T, Karimi M, Marsh JL, Milovanovic T, Lin F, Holcombe RF. Expression of secreted Wnt antagonists in gastrointestinal tissues: potential role in stem cell homeostasis. J Clin Pathol. 2005 May; 58(5):515-9.
      View in: PubMed
    36. Milovanovic T, Planutis K, Nguyen A, Marsh JL, Lin F, Hope C, Holcombe RF. Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int J Oncol. 2004 Nov; 25(5):1337-42.
      View in: PubMed
    37. Holcombe RF, Kong KM, Wimmer D. Combined topoisomerase I inhibition for the treatment of metastatic colon cancer. Anticancer Drugs. 2004 Jul; 15(6):569-74.
      View in: PubMed
    38. Pham K, Milovanovic T, Barr RJ, Truong T, Holcombe RF. Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features. Mol Pathol. 2003 Oct; 56(5):280-5.
      View in: PubMed
    39. Sommers KR, Kong KM, Bui DT, Fruehauf JP, Holcombe RF. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs. 2003 Sep; 14(8):659-62.
      View in: PubMed
    40. Holcombe RF, Gu M, Imagawa D, Milovanovic T. Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571). Anticancer Drugs. 2003 Sep; 14(8):651-7.
      View in: PubMed
    41. Gottschalk LA, Holcombe RF, Jackson D, Bechtel RJ. The effects of anticancer chemotherapeutic drugs on cognitive function and other neuropsychiatric dimensions in breast cancer patients. Methods Find Exp Clin Pharmacol. 2003 Mar; 25(2):117-22.
      View in: PubMed
    42. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, Truong T. Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol. 2002 Aug; 55(4):220-6.
      View in: PubMed
    43. Cerussi AE, Jakubowski D, Shah N, Bevilacqua F, Lanning R, Berger AJ, Hsiang D, Butler J, Holcombe RF, Tromberg BJ. Spectroscopy enhances the information content of optical mammography. J Biomed Opt. 2002 Jan; 7(1):60-71.
      View in: PubMed
    44. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J, Holcombe RF, Waterman ML. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet. 2001 May; 28(1):53-7.
      View in: PubMed
    45. Cerussi AE, Berger AJ, Bevilacqua F, Shah N, Jakubowski D, Butler J, Holcombe RF, Tromberg BJ. Sources of absorption and scattering contrast for near-infrared optical mammography. Acad Radiol. 2001 Mar; 8(3):211-8.
      View in: PubMed
    46. Holcombe RF, Milovanovic T, Stewart RM, Brodhag TM. Investigating the role of immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints. Cancer Detect Prev. 2001; 25(2):183-91.
      View in: PubMed
    47. Kannan K, Holcombe RF, Jain SK, Alvarez-Hernandez X, Chervenak R, Wolf RE, Glass J. Evidence for the induction of apoptosis by endosulfan in a human T-cell leukemic line. Mol Cell Biochem. 2000 Feb; 205(1-2):53-66.
      View in: PubMed
    48. Kashuk KB, Harmelin E, Holcombe R, Goggin J. Arthroscopy of the ankle and subtalar joint. Clin Podiatr Med Surg. 2000 Jan; 17(1):55-79, vi.
      View in: PubMed
    49. Holcombe RF, Jacobson J, Dakhil SR, Stewart RM, Betzing KS, Kannan K, Macdonald JS. Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009. Cancer Immunol Immunother. 1999 Dec; 48(9):533-9.
      View in: PubMed
    50. Holcombe RF, Jacobson J, Li A, Moinpour CM. Inclusion of black Americans in oncology clinical trials: the Louisiana State University Medical Center experience. Am J Clin Oncol. 1999 Feb; 22(1):18-21.
      View in: PubMed
    51. Davis TC, Holcombe RF, Berkel HJ, Pramanik S, Divers SG. Informed consent for clinical trials: a comparative study of standard versus simplified forms. J Natl Cancer Inst. 1998 May 6; 90(9):668-74.
      View in: PubMed
    52. Zibari GB, Riche A, Zizzi HC, McMillan RW, Aultman DF, Boykin KN, Gonzalez E, Nandy I, Dies DF, Gholson CF, Holcombe RF, McDonald JC. Surgical and nonsurgical management of primary and metastatic liver tumors. Am Surg. 1998 Mar; 64(3):211-20; discussion 220-1.
      View in: PubMed
    53. Cain MS, Burton GV, Holcombe RF. Fatal leukoencephalopathy in a patient with non-Hodgkin's lymphoma treated with CHOP chemotherapy and high-dose steroids. Am J Med Sci. 1998 Mar; 315(3):202-7.
      View in: PubMed
    54. Holcombe RF, Li A, Stewart RM. Levamisole and interleukin-2 for advanced malignancy. Biotherapy. 1998; 11(4):255-8.
      View in: PubMed
    55. Barbosa MD, Barrat FJ, Tchernev VT, Nguyen QA, Mishra VS, Colman SD, Pastural E, Dufourcq-Lagelouse R, Fischer A, Holcombe RF, Wallace MR, Brandt SJ, de Saint Basile G, Kingsmore SF. Identification of mutations in two major mRNA isoforms of the Chediak-Higashi syndrome gene in human and mouse. Hum Mol Genet. 1997 Jul; 6(7):1091-8.
      View in: PubMed
    56. Holcombe RF. The question remains: oncology and primary care. J Clin Oncol. 1997 Mar; 15(3):1285-6.
      View in: PubMed
    57. Holcombe RF. Crisis in medical research. Acad Med. 1997 Jan; 72(1):1.
      View in: PubMed
    58. Kingsmore SF, Barbosa MD, Tchernev VT, Detter JC, Lossie AC, Seldin MF, Holcombe RF. Positional cloning of the Chediak-Higashi syndrome gene: genetic mapping of the beige locus on mouse chromosome 13. J Investig Med. 1996 Oct; 44(8):454-61.
      View in: PubMed
    59. Kannan K, Stewart RM, Bounds W, Carlsson SR, Fukuda M, Betzing KW, Holcombe RF. Lysosome-associated membrane proteins h-LAMP1 (CD107a) and h-LAMP2 (CD107b) are activation-dependent cell surface glycoproteins in human peripheral blood mononuclear cells which mediate cell adhesion to vascular endothelium. Cell Immunol. 1996 Jul 10; 171(1):10-9.
      View in: PubMed
    60. Berkel H, Holcombe RF, Middlebrooks M, Kannan K. Nonsteroidal antiinflammatory drugs and colorectal cancer. Epidemiol Rev. 1996; 18(2):205-17.
      View in: PubMed
    61. Kannan K, Divers SG, Lurie AA, Chervenak R, Fukuda M, Holcombe RF. Cell surface expression of lysosome-associated membrane protein-2 (lamp2) and CD63 as markers of in vivo platelet activation in malignancy. Eur J Haematol. 1995 Sep; 55(3):145-51.
      View in: PubMed
    62. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol. 1995 Jun; 13(6):1303-11.
      View in: PubMed
    63. Divers SG, Kannan K, Stewart RM, Betzing KW, Dempsey D, Fukuda M, Chervenak R, Holcombe RF. Quantitation of CD62, soluble CD62, and lysosome-associated membrane proteins 1 and 2 for evaluation of the quality of stored platelet concentrates. Transfusion. 1995 Apr; 35(4):292-7.
      View in: PubMed
    64. Holcombe RF, Baethge BA, Wolf RE, Betzing KW, Stewart RM. Natural killer cells and gamma delta T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies. Ann Rheum Dis. 1995 Jan; 54(1):69-72.
      View in: PubMed
    65. Rypkema SW, Holcombe RF. The role of the hematologist/oncologist as a primary care provider. Am J Med Sci. 1994 Dec; 308(6):360-4.
      View in: PubMed
    66. Holcombe RF. Clinical applications of the interleukins: present and future. J La State Med Soc. 1994 Nov; 146(11):479-83.
      View in: PubMed
    67. Holcombe RF. Informed consent, cancer, and truth in prognosis. N Engl J Med. 1994 Sep 22; 331(12):811; author reply 811-2.
      View in: PubMed
    68. Bounds W, Betzing KW, Stewart RM, Holcombe RF. Social drinking and the immune response: impairment of lymphokine-activated killer activity. Am J Med Sci. 1994 Jun; 307(6):391-5.
      View in: PubMed
    69. Holcombe RF, Stewart RM, Betzing KW, Kannan K. Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil. Cancer Immunol Immunother. 1994 Jun; 38(6):394-8.
      View in: PubMed
    70. Holcombe RF, Baethge BA, Wolf RE, Betzing KW, Stewart RM, Hall VC, Fukuda M. Correlation of serum interleukin-8 and cell surface lysosome-associated membrane protein expression with clinical disease activity in systemic lupus erythematosus. Lupus. 1994 Apr; 3(2):97-102.
      View in: PubMed
    71. Holcombe RF, Jones KL, Stewart RM. Lysosomal enzyme activities in Chediak-Higashi syndrome: evaluation of lymphoblastoid cell lines and review of the literature. Immunodeficiency. 1994; 5(2):131-40.
      View in: PubMed
    72. Campbell LC, Von Burton G, Holcombe RF. Transfusion therapy in sickle cell disease patients: methods and acute indications. J La State Med Soc. 1993 Dec; 145(12):515-21.
      View in: PubMed
    73. Goodrich KH, Alvarez X, Holcombe RF. Effect of levamisole on major histocompatibility complex class I expression in colorectal and breast carcinoma cell lines. Cancer. 1993 Jul 1; 72(1):225-30.
      View in: PubMed
    74. Holcombe RF, Baethge BA, Stewart RM, Betzing K, Hall VC, Fukuda M, Wolf RE. Cell surface expression of lysosome-associated membrane proteins (LAMPs) in scleroderma: relationship of lamp2 to disease duration, anti-Sc170 antibodies, serum interleukin-8, and soluble interleukin-2 receptor levels. Clin Immunol Immunopathol. 1993 Apr; 67(1):31-9.
      View in: PubMed
    75. Holcombe RF. Mini-dose interferon alpha-2a in the treatment of myelodysplasia. Leukemia. 1993 Feb; 7(2):192-5.
      View in: PubMed
    76. Holcombe RF, Griffin J. Effect of insurance status on pain medication prescriptions in a hematology/oncology practice. South Med J. 1993 Feb; 86(2):151-6.
      View in: PubMed
    77. Jones KL, Stewart RM, Fowler M, Fukuda M, Holcombe RF. Chediak-Higashi lymphoblastoid cell lines: granule characteristics and expression of lysosome-associated membrane proteins. Clin Immunol Immunopathol. 1992 Dec; 65(3):219-26.
      View in: PubMed
    78. Holcombe RF. Underinsurance in America. N Engl J Med. 1992 Nov 12; 327(20):1461-2.
      View in: PubMed
    79. Holcombe RF. Interleukin-2-induced cytotoxicity of Chediak-Higashi lymphocytes. Acta Haematol. 1992; 87(1-2):45-8.
      View in: PubMed
    80. Holcombe RF, Stephenson DA, Zweidler A, Stewart RM, Chapman VM, Seidman JG. Linkage of loci associated with two pigment mutations on mouse chromosome 13. Genet Res. 1991 Aug; 58(1):41-50.
      View in: PubMed
    81. Holcombe RF, Treseler PA, Rosenthal DS. Chronic myelomonocytic leukemia transformation in polycythemia vera. Leukemia. 1991 Jul; 5(7):606-10.
      View in: PubMed
    82. Maas RL, Jepeal LI, Elfering SL, Holcombe RF, Morton CC, Eddy RL, Byers MG, Shows TB, Leder P. A human gene homologous to the formin gene residing at the murine limb deformity locus: chromosomal location and RFLPs. Am J Hum Genet. 1991 Apr; 48(4):687-95.
      View in: PubMed
    83. Holcombe RF, van de Griend R, Ang SL, Bolhuis RL, Seidman JG. Gamma-delta T cells in Chediak-Higashi syndrome. Acta Haematol. 1990; 83(4):193-7.
      View in: PubMed
    84. Holcombe RF. Drug-induced granulocytopenia with natural killer lymphocytosis after renal transplantation. Acta Haematol. 1990; 83(2):96-8.
      View in: PubMed
    85. Jarcho JA, McKenna W, Pare JA, Solomon SD, Holcombe RF, Dickie S, Levi T, Donis-Keller H, Seidman JG, Seidman CE. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. 1989 Nov 16; 321(20):1372-8.
      View in: PubMed
    86. Tepler I, Morton CC, Shimizu A, Holcombe RF, Eddy R, Shows TB, Leder P. The gene for the human mast cell high-affinity IgE receptor alpha chain: chromosomal localization to Iq21-q23 and RFLP analysis. Am J Hum Genet. 1989 Nov; 45(5):761-5.
      View in: PubMed
    87. Holcombe RF, Strauss W, Owen FL, Boxer LA, Warren RW, Conley ME, Ferrara J, Leavitt RY, Fauci AS, Taylor BA, et al. Relationship of the genes for Chediak-Higashi syndrome (beige) and the T-cell receptor gamma chain in mouse and man. Genomics. 1987 Nov; 1(3):287-91.
      View in: PubMed
    88. Opdyke DF, Wilde DW, Holcombe RF. Effect of angiotensin II on vascular resistance in whole-body perfused dogfish. Comp Biochem Physiol C. 1982; 73(1):45-9.
      View in: PubMed
    89. Opdyke DF, Holcombe RF. Effect of angiotensins and epinephrine on vascular resistance of isolated dogfish gut. Am J Physiol. 1978 May; 234(5):R196-200.
      View in: PubMed
    90. Opdyke DF, Holcombe R. Response to angiotensins I and II and to AI-converting-enzyme inhibitor in a shark. Am J Physiol. 1976 Dec; 231(6):1750-3.
      View in: PubMed
    91. HOLCOMBE R. Cerebro vascular accident. Med Times. 1958 Aug; 86(8):963-7.
      View in: PubMed
    92. HOLCOMBE R. The binge drinker's liver. Med Times. 1957 Jul; 85(7):769-73.
      View in: PubMed
    93. HOLCOMBE R. Tolerance of surgical procedures. Med Times. 1956 Aug; 84(8):826-37.
      View in: PubMed
    Holcombe's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067